Company / Return on Assets (ROA)
LENZ Therapeutics, Inc. Return on Assets (ROA) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-26.9%
FY2025
5-year range
-99.4% / -17.6%
FY2021-FY2025
Trend
-16.1%
vs FY2024
Sector context
#120 of 213
Health Care
What the data says
At -26.9%, LENZ Therapeutics, Inc.'s return on assets (roa) ranks #120 of 213 in the Health Care sector. Improved from -99.4% to -26.9% over the past 2 years.
Based on SEC 10-K filings.
-26.9% in FY2025 with a 3-year CAGR of +4.5%.
Improved from -99.4% to -26.9% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +4.5pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#120 of 213 in Health CareTop 56% of 213This company -26.9% Sector average -24.1%
▼
-11.2% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 16.1% year-over-year.
- Currently 2.7pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2021.
- Lowest return on assets (roa) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -26.9% | -16.1% |
| FY2024 | -23.1% | +76.7% |
| FY2023 | -99.4% | -216.7% |
| FY2022 | -31.4% | -78.4% |
| FY2021 | -17.6% | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026